Gynecology & Obstetrics

Prostate cancer is the most common male cancer in the UK, accounting for 25% of all new male cancers. Age related, the incidence rises sharply from 50 years of age with the highest incidence in those 75-80 years and higher incidence in men of Afro-Caribbean descent. If a tumour starts to develop on active surveillance or is thought to be intermediate/high risk localised disease, surgical removal of the prostate may be advised.  Surgery is the main treatment for penile cancer where the tumours are very small this may be laser surgery or cryosurgery. Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate of 10.40%, from $18 billion in 2015 to $36 billion in 2022.